Aerium Therapeutics, Inc.
Aerium Therapeutics has ended operations. For matters requiring attention, contact the respective offices in Switzerland and the USA. The company was involved in therapeutic development, but is no longer operational.
Industries
Nr. of Employees
small (1-50)
Aerium Therapeutics, Inc.
Products
AER800
A combination of two long-acting monoclonal antibodies, AER003 and AER004, designed to protect immunocompromised individuals from severe COVID-19 by targeting the ACE2 binding site of the SARS-CoV-2 receptor binding domain.
AER003
A monoclonal antibody that binds to the receptor binding domain of SARS-CoV-2, providing a high barrier to virus escape.
AER004
A monoclonal antibody that blocks the receptor binding domain of SARS-CoV-2 in a complementary manner to AER003.
AER005
A monoclonal antibody targeting a novel, highly conserved region of SARS-CoV-2 outside of the receptor binding domain.
AER-002
A monoclonal antibody being evaluated for the treatment of Long COVID, particularly in individuals with long-term symptoms from previous COVID-19 variants.
Antibody Discovery Platform
A platform that supports the discovery and development of new monoclonal antibodies against SARS-CoV-2 and other viral threats.
AER800
A combination of two long-acting monoclonal antibodies, AER003 and AER004, designed to protect immunocompromised individuals from severe COVID-19 by targeting the ACE2 binding site of the SARS-CoV-2 receptor binding domain.
AER003
A monoclonal antibody that binds to the receptor binding domain of SARS-CoV-2, providing a high barrier to virus escape.
AER004
A monoclonal antibody that blocks the receptor binding domain of SARS-CoV-2 in a complementary manner to AER003.
AER005
A monoclonal antibody targeting a novel, highly conserved region of SARS-CoV-2 outside of the receptor binding domain.
AER-002
A monoclonal antibody being evaluated for the treatment of Long COVID, particularly in individuals with long-term symptoms from previous COVID-19 variants.
Antibody Discovery Platform
A platform that supports the discovery and development of new monoclonal antibodies against SARS-CoV-2 and other viral threats.